News

Edaravone dexborneol before thrombectomy improved 90-day independence only in LVO stroke patients with clinical-radiological mismatch in TASTE-2.

A TETON-2 post hoc analysis at CHEST 2026 found 126 progression events with inhaled treprostinil vs 161 with placebo across 52 weeks.

Alia Galadari, MD, discusses subtle erythema, commonly missed diagnoses, and research gaps to help clinicians recalibrate their approach to skin of color.

Balcinrenone lowered systolic BP by 14.1 mm Hg in stage 3 CKD, while combination therapy preserved dapagliflozin's glucosuric effect.

This Q&A interview segment with Harrison Nguyen, MD, MBA, MPH, highlights key points made during his 2026 Fall Clinical Dermatology meeting sessions.

Stay updated with the latest healthcare breakthroughs, including Otsuka’s sibeprenlimab 24-month eGFR data in IgA nephropathy.

James Tumlin, MD, discusses RAINIER's proteinuria findings, dual APRIL/BAFF inhibition, safety, and the upcoming FDA decision.

In 1200 patients with solid tumors, creatinine-based eGFR identified CKD in 10.2% vs 18.9% by measured GFR, often missing chemotherapy dosing cutoffs.

Phase 2 BESTOW patient-reported outcomes show greater quality-of-life gains and fewer medication-related symptoms with tegoprubart vs tacrolimus at 1 year.

Longer GLP-1 RA exposure was also associated with a lower hospitalization burden in a cohort of 5,897 patients with type 2 diabetes.

A Kidney Week 2026 survey examines why patients miss dialysis, when barriers arise, and how outreach relates to rescheduling.

Jessica Kendrick, MD, MPH, discusses phase 3 PATH data showing upacicalcet reduced iPTH in hemodialysis patients with secondary hyperparathyroidism.

Christopher Chan, MD, discusses why digital counseling was linked to higher home KRT uptake only among motivationally ready patients with CKD.

Early RENEW-HD data support moving the 13 kg Neokidney to autonomous use testing, with dialysate calcium adjustments planned.

Jicheng Lv, MD, joins Brendon Neuen, MBBS, PhD, and Shikha Wadhwani, MD, MS, to discuss 2-year TELIGAN data for telitacicept in IgAN.

A PROTECT biomarker analysis shows sparsentan reduced urinary sCD163, BAFF, C5b-9, and IL-6 vs irbesartan through 110 weeks in IgA nephropathy.

Diana Isaacs, PharmD, and Natalie Bellini, DNP, review early MiniMed Vivera data on optional meal announcements and twiist's new type 2 diabetes clearance.

Jean Bourbeau, MD, says AI analysis of CT scans is not ready for routine use but could reshape early COPD diagnosis as GOLD expands its AI guidance.

Hugh Gallagher, MBBS, PhD, discusses a 27% lower point estimate for cardiovascular events with aspirin that was not significant.

Real-world data in 1477 patients on dialysis show tenapanor reduced serum phosphate at 6 months with or without background phosphate binders.

Approval rests on the phase 3 AFFIRM trial, in which 56% of patients reached clinical remission at week 12 vs 30% with placebo.

Sarina Berger Elmariah, MD, PhD, MPH, reviews 3-year nemolizumab data showing deeper skin clearance and lasting itch relief in atopic dermatitis responders.

Jean Elwing, MD, discusses what drove ralinepag's reduction in PAH clinical worsening in ADVANCE Outcomes and where the it could fit if approved.

Jean Elwing, MD, discusses a CHEST 2026 subgroup analysis showing ralinepag reduces clinical worsening in PAH even among patients with low-risk criteria.

Serum bicarbonate did not differ significantly between weekly produce delivery and sodium bicarbonate in a 12-month CKD trial.

In a randomized crossover trial, a liberalized produce diet raised urinary potassium excretion without changing serum potassium.

Participants described earlier phenotyping, closer tracking of steroid exposure, and recognizing gradual gains on biologic therapy.

Interim IMAgINATION data show the once-monthly factor B antisense therapy sefaxersen reduced proteinuria by 43.1% vs placebo at week 37 in IgA nephropathy.